(firstQuint)Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole.

 This is an open-label Phase 1b, dose escalation study of oral ARQ 092 administered in combination with carboplatin plus paclitaxel (Carboplatin Plus Paclitaxel Arm) or in combination with paclitaxel alone (Paclitaxel Arm) in subjects with advanced, inoperable metastatic and/or recurrent solid tumors, or in combination with anastrozole (Anastrozole Arm) in subjects with ovarian or endometrial cancer.

 Only subjects with endometrial cancer will be enrolled in the Expansion Cohort of the Anastrozole Arm,.

 Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole@highlight

An Open-label Phase 1b Study of ARQ 092 in Combination with Carboplatin Plus Paclitaxel, in Combination with Paclitaxel, or in Combination with Anastrozole in Subjects with Selected Solid Tumors